Biomarker-guided classification scheme of neurodegenerative diseases

Journal of Sport and Health Science

Volumn 5, Issue 4, 2016, Pages 383-387

  Baldacci, Filippo ^a,b,c   Lista, Simone ^b,c   Garaci, Francesco ^d,e   Bonuccelli, Ubaldo ^a   Toschi, Nicola ^d,f   Hampel, Harald ^b,c  

^a UNIVERSITY OF PISA   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e Department of Imaging   (Italy)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AUTOPSY; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; NEUROPATHOLOGY; NOTE; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PREVALENCE; PROTEIN MISFOLDING; SENSITIVITY AND SPECIFICITY;

EID: 85000962084     PISSN: 20952546     EISSN: 22132961     Source Type: Journal    
DOI: 10.1016/j.jshs.2016.08.007     Document Type: Note

References (25)

1. 1 Fiest, K.M., Roberts, J.I., Maxwell, C.J., Hogan, D.B., Smith, E.E., Frolkis, A., et al. The prevalence and incidence of dementia due to Alzheimer's disease: a systematic review and meta-analysis. Can J Neurol Sci 43:Suppl. 1 (2016), S51–82.
2. 2 Kalia, L.V., Lang, A.E., Parkinson's disease. Lancet 386 (2015), 896–912.
3. 3 Scheltens, P., Blennow, K., Breteler, M.M.B., de Strooper, B., Frisoni, G.B., Salloway, S., et al. Alzheimer's disease. Lancet 388 (2016), 505–517.
4. 4 Warren, J.D., Rohrer, J.D., Schott, J.M., Fox, N.C., Hardy, J., Rossor, M.N., Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci 36 (2013), 561–569.
5. 5 Kovacs, G.G., Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci, 17, 2016, 10.3390/ijms17020189 pii: E189.
6. 6 Pievani, M., de Haan, W., Wu, T., Seeley, W.W., Frisoni, G.B., Functional network disruption in the degenerative dementias. Lancet Neurol 10 (2011), 829–843.
7. 7 Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
8. 8 Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8 (2012), 1–13.
9. 9 Alexander, S.K., Rittman, T., Xuereb, J.H., Bak, T.H., Hodges, J.R., Rowe, J.B., Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85 (2014), 925–929.
10. 10 Hughes, A.J., Daniel, S.E., Ben-Shlomo, Y., Lees, A.J., The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002), 861–870.
11. 11 Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998), 1546–1554.
12. 12 Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R.C., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47 (1996), 1–9.
13. 13 McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005), 1863–1872.
14. 14 Knopman, D.S., DeKosky, S.T., Cummings, J.L., Chui, H., Corey-Bloom, J., Relkin, N., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001), 1143–1153.
15. 15 McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
16. 16 Walker, Z., Possin, K.L., Boeve, B.F., Aarsland, D., Lewy body dementias. Lancet 386 (2015), 1683–1697.
17. 17 Bang, J., Spina, S., Miller, B.L., Frontotemporal dementia. Lancet 386 (2015), 1672–1682.
18. 18 O'Brien, J.T., Thomas, A., Vascular dementia. Lancet 386 (2015), 1698–1706.
19. 19 Kovacs, G.G., Milenkovic, I., Wöhrer, A., Höftberger, R., Gelpi, E., Haberler, C., et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 126 (2013), 365–384.
20. 20 Lista, S., Garaci, F.G., Toschi, N., Hampel, H., Imaging epigenetics in Alzheimer's disease. Curr Pharm Des 19 (2013), 6393–6415.
21. 21 Reitz, C., Toward precision medicine in Alzheimer's disease. Ann Transl Med, 4, 2016, 107, 10.21037/atm.2016.03.05.
22. 22 Hampel, H., Lista, S., Khachaturian, Z.S., Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8 (2012), 312–336.
23. 23 Jack, C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Feldman, H.H., Frisoni, G.B., et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87 (2016), 539–547.
24. 24 Younesi, E., Hofmann-Apitius, M., From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J, 4, 2013, 23, 10.1186/1878-5085-4-23.
25. 25 Dubois, B., Hampel, H., Feldman, H.H., Scheltens, P., Aisen, P., Andrieu, S., et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12 (2016), 292–323.